This technique uses antibodies against CD45 to isolate and remove contaminated leukocytes from the samples, followed by the capture of targeted CTCs by using specific antibodies to detect tumor-associated antigens which are expressed on the surface of CTCs [64]. The gene discussed is PTPRC; the disease is neoplasm.